Company intelligence / Profile preview
Assembly Biosciences, Inc.
South San Francisco, California, United Statesassemblybio.com ↗
- Ownership
- Public · ASMB
- Employees
- ~73
- Development stage
- Phase 2
01
Overview
The company has multiple clinical programs including ABI-5366 and ABI-1179 in Phase 1a/1b for recurrent genital herpes, ABI-6250 in Phase 1a for hepatitis delta virus, and ABI-4334 in Phase 1b for hepatitis B virus treatment[5].
- Therapeutic areas
- Infectious Diseases
- Modalities
- Small moleculesantivirals
- Industry
- Biotech
02
Drug pipeline
9 assets8 more assets in the full pipeline.
03
Partnerships
Gilead Sciences, Inc.BeiGene, Ltd.
04
Financials
- Market cap
- $407.2M
- Total revenue
- $72.3M
- Enterprise value
- $89.2M
Beyond the preview
Go deeper on Assembly Biosciences, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Assembly Biosciences, Inc..